Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
The endocannabinoid system and multiple sclerosis.
Reassessing the risk of natalizumab-associated PML.
The role of global and regional gray matter volume decrease in multiple sclerosis.
Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
BRIEF: Teva files for Copaxone-Laquinimod patent
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity
Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease.

Pages